Ordenar

Buscar

01/01/2023 Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis
Matabuena M., Salgado F.J., Nieto-Fontarigo J.J., Álvarez-Puebla M.J., Arismendi E., Barranco P., Bobolea I., Caballero M.L., Cañas J.A., Cárdaba B., Cruz M.J., Curto E., Domínguez-Ortega J., Luna J.A., Martínez-Rivera C., Mullol J., Muñoz X., Rodriguez-Garcia J., Olaguibel J.M., Picado C., Plaza V., Quirce S., Rial M.J., Romero-Mesones C., Sastre B., Soto-Retes L., Valero A., Valverde-Monge M., Del Pozo V., Sastre J., González-Barcala F.J.. Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis. ARCHIVOS DE BRONCONEUMOLOGIA. 2023; 59(4)DOI:10.1016/j.arbres.2023.01.007. PMID:36732158. IF:8.700(Q1/1D).
01/01/2023 Post-TB bronchiectasis: from pathogenesis to rehabilitation
Martinez-Garcia M.A., Guan W.-J., de-La-Rosa D., Athanazio R., Oscullo G., Shi M.-X., Pujal-Montaña P., Endlich B.N., Tiberi S., Centis R., Migliori G.B.. Post-TB bronchiectasis: from pathogenesis to rehabilitation. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. 2023; 27(3)DOI:10.5588/ijtld.22.0566. PMID:36855043. IF:3.800(Q1/3D).
01/01/2023 Remote visits for severe asthma patients after the COVID-19 pandemic: How to address the challenge?
Sánchez-García S., Soto-Retes L., Chiner E., Cisneros C.. Remote visits for severe asthma patients after the COVID-19 pandemic: How to address the challenge?. REVISTA CLINICA ESPANOLA. 2023; 223(3)DOI:10.1016/j.rce.2023.01.009. PMID:36736728. IF:2.300(Q2/3D).
01/01/2023 Differentiation using minimally-invasive bioimpedance measurements of healthy and pathological lung tissue through bronchoscopy
Company-Se G., Nescolarde L., Pajares V., Torrego A., Riu P.J., Rosell J., Bragós R.. Differentiation using minimally-invasive bioimpedance measurements of healthy and pathological lung tissue through bronchoscopy. Frontiers in Medicine. 2023; 10DOI:10.3389/fmed.2023.1108237. PMID:37113605. IF:3.100(Q1/2D).
01/01/2023 Combined Pulmonary Fibrosis and Emphysema Syndrome: What is the Role of Airflow Limitation?
Moya-Álvarez V., Castillo Villegas D., de Miguel Díez J.. Combined Pulmonary Fibrosis and Emphysema Syndrome: What is the Role of Airflow Limitation?. Open Respiratory Archives. 2023; 5(1)DOI:10.1016/j.opresp.2023.100233. PMID:37497242. IF:(Q/D).
01/01/2023 Bronchiectasis-COPD Overlap Syndrome: Role of Peripheral Eosinophil Count and Inhaled Corticosteroid Treatment
Oscullo G., Gómez-Olivas J.D., Ingles M., Mompean S., Martinez-Perez R., Suarez-Cuartin G., Rosa-Carrillo D.L., Martinez-Garcia M.A.. Bronchiectasis-COPD Overlap Syndrome: Role of Peripheral Eosinophil Count and Inhaled Corticosteroid Treatment. Journal of Clinical Medicine. 2023; 12(19)DOI:10.3390/jcm12196417. PMID:37835060. IF:3.000(Q1/2D).
01/01/2023 Validation of the Asthma Impairment and Risk Questionnaire in Spain: A Useful Tool for Assessing Asthma Control in Adolescents and Adults
Perez de Llano L., Martínez Moragón E., Entrenas L.M., Martínez Rivera C., Cisneros C., Blanco-Aparicio M., Trisán A., Plaza V., Ramos J., Funenga Fitas E., Sanchez-Covisa J., Dominguez-Ortega J.. Validation of the Asthma Impairment and Risk Questionnaire in Spain: A Useful Tool for Assessing Asthma Control in Adolescents and Adults. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2023; 33(5)DOI:10.18176/jiaci.0881. PMID:36520522. IF:6.700(Q1/2D).
01/01/2023 Pulmonary Complications Following Hematopoietic Stem Cell Transplantation: Radiological Considerations
Franquet T., Giménez A., Mazzini S.. Pulmonary Complications Following Hematopoietic Stem Cell Transplantation: Radiological Considerations. Applied Psychology Readings: Selected Papers From The Singapore Conference On Applied Psychology 2022. 2023; DOI:10.1007/978-3-031-28797-8_6. PMID:. IF:(Q/D).
01/01/2023 Persistent Respiratory Failure and Re-Admission in Patients with Chronic Obstructive Pulmonary Disease Following Hospitalization for COVID-19
Figueira-Gonçalves, JM, García-Bello, MA, Ramallo-Fariña, Y, Méndez, R, Campos, AL, González-Jiménez, P, Peces-Barba, G, Molina-Molina, M, España, PP, García, E, Domínguez-Pazos, SD, Clemente, MG, Panadero, C, de la Rosa-Carrillo, D, Sibila, O, Martínez-Pitarch, MD, Toledo-Pons, N, López-Ramirez, C, Almonte-Batista, W, Macías-Paredes, A, Redenes-Bonet, D, Pérez-Rodas, EN, Lázaro, J, Fernández, SQ, Cordovilla, R, Cano-Pumarega, I, Torres, A, Menendez, R. Persistent Respiratory Failure and Re-Admission in Patients with Chronic Obstructive Pulmonary Disease Following Hospitalization for COVID-19. International Journal of Chronic Obstructive Pulmonary Disease. 2023; 18DOI:10.2147/COPD.S428316. PMID:37955022. IF:2.700(Q2/5D).
01/01/2023 Reply to "Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies"
Barroso, B, Valverde-Monge, M, Alobid,, Olaguibel, J, Rial, M, Quirce, S, Arismendi, E, Barranco, P, Betancor, D, Bobolea,, Cardaba, B, Carmona, MC, Curto, E, Dominguez-Ortega, J, Gonzalez-Barcala, F, Martinez-Rivera, C, Mahillo-Fernandez,, Munoz, X, Picado, C, Plaza,, Munoz, JR, Retes, LS, Valero, A, Delpozo,, Mullol, J, Sastre, J. Reply to "Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies". JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2023; 33(6)DOI:10.18176/jiaci.0953. PMID:38095497. IF:6.700(Q1/2D).
01/01/2023 Obesity-Related Single-Nucleotide Polymorphisms and Weight Gain following First-Line Antiretroviral Therapy
Berenguer J., Jarrín I., Bellón J.M., Díez C., Jiménez-Sousa M.A., Roca C., González-García J., Dalmau D., Olalla J., Herrero C., Villarroya F., Domingo P., Resino S.. Obesity-Related Single-Nucleotide Polymorphisms and Weight Gain following First-Line Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES. 2023; 76(6)DOI:10.1093/cid/ciac880. PMID:36345912. IF:(Q/D).
01/01/2023 Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study
Martín-Iguacel R., Vazquez-Friol M.C., Burgos J., Bruguera A., Reyes-Urueña J., Moreno-Fornés S., Aceitón J., Díaz Y., Domingo P., Saumoy M., Knobel H., Dalmau D., Borjabad B., Johansen I.S., Miro J.M., Casabona J., Llibre J.M.. Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study. Frontiers in Medicine. 2023; 10DOI:10.3389/fmed.2023.1182359. PMID:37415770. IF:3.100(Q1/2D).
01/01/2023 Repetitive ambulatory levosimendan as a bridge to heart transplantation
de Juan Bagudá J., de Frutos F., López-Vilella R., Couto Mallón D., Guzman-Bofarull J., Blazquez-Bermejo Z., Cobo-Belaustegui M., Mitroi C., Pastor-Pérez F.J., Moliner-Abós C., Rangel-Sousa D., Díaz-Molina B., Tobar-Ruiz J., Salterain Gonzalez N., García-Pinilla J.M., García-Cosío Carmena M.D., Crespo-Leiro M.G., Dobarro D., Almenar L., Delgado-Jiménez J.F., Paredes-Galán E., González-Vílchez F., González-Costello J.. Repetitive ambulatory levosimendan as a bridge to heart transplantation. REVISTA ESPANOLA DE CARDIOLOGIA. 2023; DOI:10.1016/j.recesp.2023.07.005. PMID:. IF:(Q/D).
01/01/2023 A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study
Isla D., Felip E., Garrido P., Insa A., Majem M., Remon J., Trigo J.M., de Castro J.. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Clinical & Translational Oncology. 2023; 25(1)DOI:10.1007/s12094-022-02941-5. PMID:36168085. IF:2.800(Q2/5D).
01/01/2023 Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
Peters S., Letovanec I., Mauer M., Dafni U., Ejedepang D., Biernat W., Bubendorf L., Warth A., Pokharel S., Reinmuth N., Tarruella, MM, Casas-Martin J., Tsourti Z., Marti N., Kammler R., Danson S., O'Brien M., Stahel R.A.. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. LUNG CANCER. 2023; 175DOI:10.1016/j.lungcan.2022.12.004. PMID:36535121. IF:4.500(Q1/2D).
01/01/2023 Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast
John T., Majem M., Legg D., Goldman J.. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Targeted Oncology. 2023; 18(1)DOI:10.1007/s11523-022-00927-5. PMID:36534268. IF:4.400(Q2/3D).
01/01/2023 Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review
Blakely C.M., Weder W., Bubendorf L., He J., Majem M., Shyr Y., Chaft J.E.. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. LUNG CANCER. 2023; 177DOI:10.1016/j.lungcan.2023.01.002. PMID:36736076. IF:4.500(Q1/2D).
01/01/2023 Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Vidal J., Fernández-Rodríguez M.C., Casadevall D., García-Alfonso P., Páez D., Guix M., Alonso V., Cano M.T., Santos C., Durán G., Elez E., Manzano J.L., Garcia-Carbonero R., Ferreiro R., Losa F., Pineda E., Sastre J., Rivera F., Bellosillo B., Tabernero J., Aranda E., Salazar R., Montagut C.. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. CLINICAL CANCER RESEARCH. 2023; 29(2)DOI:10.1158/1078-0432.CCR-22-1696. PMID:36074154. IF:10.400(Q1/1D).
01/01/2023 Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section
Martinez D.A.S., Quilez-Cutillas A., Jimenez-Labaig P., Sesma A., Tarazona N., Pacheco-Barcia V., Obispo B., Paez D., Quintanar T., Sanchez-Canovas M., Montes A.F., Felip E., Rodriguez-Lescure A., Elez E.. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02989-3. PMID:36418642. IF:2.800(Q2/5D).
01/01/2023 Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)
Karachaliou N., Codony-Servat J., Teixidó C., Pilotto S., Drozdowskyj A., Codony-Servat C., Giménez-Capitán A., Molina-Vila M.A., Bertrán-Alamillo J., Gervais R., Massuti B., Morán T., Majem M., Felip E., Carcereny E., García-Campelo R., Viteri S., González-Cao M., Morales-Espinosa D., Verlicchi A., Crisetti E., Chaib I., Santarpia M., Luis Ramírez J., Bosch-Barrera J., Felipe Cardona A., de Marinis F., López-Vivanco G., Miguel Sánchez J., Vergnenegre A., Sánchez Hernández J.J., Sperduti I., Bria E., Rosell R.. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499). Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-30374-9. PMID:36869103. IF:3.800(Q1/2D).
01/01/2023 Immunogenicity of COVID-19 vaccines in lung cancer patients
Provencio M., Estival A., Franco F., López-Vivanco G., Saigí M., Arasanz H., Diz P., Carcereny E., García J., Aguado C., Mosquera J., Iruarrizaga E., Majem M., Bosch-Barrera J., Mielgo-Rubio X., Guirado M., Juan-Vidal Ó., Blasco A., Lucía Gozálvez C., Del Barrio A., De Portugal T., López-Martín A., Serrano G., Campos B., Rubio J., Catot S., Esteban B., Martí-Ciriquian J.L., del Barco E., Calvo V.. Immunogenicity of COVID-19 vaccines in lung cancer patients. LUNG CANCER. 2023; 184DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:4.500(Q1/2D).
01/01/2023 Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
O'Donnell P.H., Milowsky M.I., Petrylak D.P., Hoimes C.J., Flaig T.W., Mar N., Moon H.H., Friedlander T.W., McKay R.R., Bilen M.A., Srinivas S., Burgess E.F., Ramamurthy C., George S., Geynisman D.M., Bracarda S., Borchiellini D., Geoffrois L., Maroto Rey J.P., Ferrario C., Carret A.-S., Yu Y., Guseva M., Homet Moreno B., Rosenberg J.E.. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(25)DOI:10.1200/JCO.22.02887. PMID:37369081. IF:42.100(Q1/1D).
01/01/2023 Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2
Tsutani Y., Goldman J.W., Dacic S., Yatabe Y., Majem M., Huang X., Chen A., van der Gronde T., He J.. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023; 24(4)DOI:10.1016/j.cllc.2023.02.002. PMID:36872181. IF:3.300(Q2/4D).
01/01/2023 Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Herbst R.S., Wu Y.-L., John T., Grohe C., Majem M., Wang J., Kato T., Goldman J.W., Laktionov K., Kim S.-W., Yu C.-J., Vu H.V., Lu S., Lee K.Y., Mukhametshina G., Akewanlop C., De Marinis F., Bonanno L., Domine M., Shepherd F.A., Urban D., Huang X., Bolanos A., Stachowiak M., Tsuboi M.. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(10)DOI:10.1200/JCO.22.02186. PMID:36720083. IF:42.100(Q1/1D).
01/01/2023 Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Grünwald V., Powles T., Eto M., Kopyltsov E., Rha S.Y., Porta C., Motzer R., Hutson T.E., Méndez-Vidal M.J., Hong S.-H., Winquist E., Goh J.C., Maroto P., Buchler T., Takagi T., Burgents J.E., Perini R., He C., Okpara C.E., McKenzie J., Choueiri T.K.. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Frontiers in Oncology. 2023; 13DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:3.500(Q2/4D).
01/01/2023 Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Fiala O., Buti S., Takeshita H., Okada Y., Massari F., Palacios G.A., Dionese M., Scagliarini S., Büttner T., Fornarini G., Myint Z.W., Galli L., Souza V.C., Pichler R., De Giorgi U., Quiroga M.N.G., Gilbert D., Popovic L., Grande E., Mammone G., Berardi R., Crabb S.J., Molina-Cerrillo J., Freitas M., Luz M., Iacovelli R., Calabrò F., Tural D., Atzori F., Küronya Z., Chiari R., Campos S., Caffo O., Fay A.P., Kucharz J., Zucali P.A., Rinck J.A., Zeppellini A., Bastos D.A., Aurilio G., Mota A., Trindade K., Ortega C., Sade J.P., Rizzo M., Vau N., Giannatempo P., Barillas A., Monteiro F.S.M., Dauster B., Cattrini C., Nogueira L., de Carvalho Fernandes R., Seront E., Aceituno L.G., Grillone F., Cutuli H.J., Fernandez M., Bassanelli M., Roviello G., Abahssain H., Procopio G., Milella M., Kopecky J., Martignetti A., Messina C., Caitano M., Inman E., Kanesvaran R., Herchenhorn D., Santini D., Manneh R., Bisonni R., Zakopoulou R., Mosca A., Morelli F., Maluf F., Soares A., Nunes F., Pinto A., Zgura A., Incorvaia L., Ansari J., Zabalza I.O., Landmesser J., Rizzo A., Mollica V., Sorgentoni G., Battelli N., Porta C., Bellmunt J., Santoni M.. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; 72(11)DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:4.600(Q1/3D).
01/01/2023 Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
Wakelee H., Liberman M., Kato T., Tsuboi M., Lee S.-H., Gao S., Chen K.-N., Dooms C., Majem M., Eigendorff E., Martinengo G.L., Bylicki O., Rodríguez-Abreu D., Chaft J.E., Novello S., Yang J., Keller S.M., Samkari A., Spicer J.D.. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6)DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96.300(Q1/1D).
01/01/2023 The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W., Gallego J.. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359231157641. PMID:36895850. IF:4.300(Q2/3D).
01/01/2023 Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A
Martin-Broto J., Martinez-Garcia J., Moura D.S., Redondo A., Gutierrez A., Lopez-Pousa A., Martinez-Trufero J., Sevilla I., Diaz-Beveridge R., Solis-Hernandez M.P., Carnero A., Perez M., Marcilla D., Garcia-Foncillas J., Romero P., Fernandez-Jara J., Lopez-Lopez D., Arribas I., Hindi N.. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1)DOI:10.1038/s41392-023-01661-8. PMID:37875500. IF:40.800(Q1/1D).
01/01/2023 Endosomal escape for cell-targeted proteins. Going out after going in
Voltà-Durán E., Parladé E., Serna N., Villaverde A., Vazquez E., Unzueta U.. Endosomal escape for cell-targeted proteins. Going out after going in. BIOTECHNOLOGY ADVANCES. 2023; 63DOI:10.1016/j.biotechadv.2023.108103. PMID:36702197. IF:12.100(Q1/1D).
01/01/2023 Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs)
Rueda A., Mendoza J.I., Alba-Castellon L., Parladé E., Voltà-Durán E., Paez D., Aviño A., Eritja R., Vázquez E., Villaverde A., Mangues R., Unzueta U.. Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs). Science China-Materials. 2023; 66(10)DOI:10.1007/s40843-023-2571-6. PMID:. IF:6.800(Q1/3D).
01/01/2023 Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
Mosquera-Orgueira, A, Perez-Encinas, M, Hernandez-Sanchez, A, Gonzalez-Martinez, T, Arellano-Rodrigo, E, Martinez-Elicegui, J, Villaverde-Ramiro, A, Raya, JM, Ayala, R, Ferrer-Marin, F, Fox, ML, Velez, P, Mora, E, Xicoy, B, Mata-Vazquez, MI, Garcia-Fortes, M, Angona, A, Cuevas, B, Senin, MA, Ramirez-Payer, A, Ramirez, MJ, Perez-Lopez, R, de Villambrosia, SG, Martinez-Valverde, C, Gomez-Casares, MT, Garcia-Hernandez, C, Gasior, M, Bellosillo, B, Steegmann, JL, Alvarez-Larran, A, Hernandez-Rivas, JM, Hernandez-Boluda, JC. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis. Hemasphere. 2023; 7(1)DOI:10.1097/HS9.0000000000000818. PMID:36570691. IF:11.900(Q1/1D).
01/01/2023 Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency
Marin-Bejar O., Romero-Moya D., Rodriguez-Ubreva J., Distefano M., Lessi F., Aretini P., Liquori A., Castaño J., Kozyra E., Kotmayer L., Bueno C., Cervera J., Rodriguez-Gallego J.C., Nomdedeu J.F., Murillo-Sanjuán L., De Heredia C.D., Pérez-Martinez A., López-Cadenas F., Martínez-Laperche C., Dorado-Herrero N., Marco F.M., Prósper F., Menendez P., Valcárcel D., Ballestar E., Bödör C., Bigas A., Catalá A., Wlodarski M.W., Giorgetti A.. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency. HAEMATOLOGICA. 2023; 108(9)DOI:10.3324/haematol.2022.282305. PMID:36815365. IF:10.100(Q1/2D).
01/01/2023 CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study
Frezza A.M., Stacchiotti S., Chibon F., Coindre, JM, Italiano A., Romagnosa C., Bagué S., Dei Tos A.P., Braglia L., Palmerini E., Quagliuolo V., Broto J.M., Pousa, AL, Grignani G., Brunello A., Blay, JY, Beveridge R.D., Lugowska I., Lesluyes T., Maestro R., Merlo F.D., Casali P.G., Gronchi A.. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. Cancer Medicine. 2023; 12(2)DOI:10.1002/cam4.5015. PMID:35848358. IF:2.900(Q2/5D).
01/01/2023 Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models
Medina-Gutiérrez E., García-León A., Gallardo A., Álamo P., Alba-Castellón L., Unzueta U., Villaverde A., Vázquez E., Casanova I., Mangues R.. Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models. Cancers. 2023; 15(1)DOI:10.3390/cancers15010085. PMID:36612081. IF:4.500(Q1/3D).
01/01/2023 Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma: Beyond Blood Eosinophils
Cosio B.G., Shafiek H., Iglesias A., Mosteiro M., Gonzalez-Piñeiro A., Rodríguez M., García-Cosío M., Busto E., Martin J., Mejías L., Benito A., López Vilaro L., Gómez C.. Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma: Beyond Blood Eosinophils. ARCHIVOS DE BRONCONEUMOLOGIA. 2023; 59(8)DOI:10.1016/j.arbres.2023.05.014. PMID:37414638. IF:8.700(Q1/1D).
01/01/2023 Complications related to the Cook-Swarz implantable Doppler probe use in head and neck microvascular reconstruction: a systematic review
Chiesa-Estomba C.M., González-García J.A., Genden E.M., Piazza C., Guntinas-Lichius O., Vander-Poorten V., Kowalski L.P., López F., Quer M., Rodrigo J.P., Sanabria Á., Fernández-Álvarez V., Suárez C., Cohen O., de Bree R., Shaha A.R., Makitie, AA, Ferlito A.. Complications related to the Cook-Swarz implantable Doppler probe use in head and neck microvascular reconstruction: a systematic review. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2023; 280(1)DOI:10.1007/s00405-022-07577-3. PMID:35941283. IF:1.900(Q2/3D).
01/01/2023 External validation of the H-index (host index) in patients with head and neck squamous cell carcinomas
Sansa A., Valero C., Holgado A., Vásquez R., Quer M., Patel S.G., León X.. External validation of the H-index (host index) in patients with head and neck squamous cell carcinomas. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2023; 45(1)DOI:10.1002/hed.27224. PMID:36225167. IF:2.400(Q1/2D).
01/01/2023 Differential characteristics of patients with squamous cell carcinoma of the head and neck with no history of tobacco or alcohol use
León X., Pujals G., Sauter B., Neumann E., Pujol A., Quer M.. Differential characteristics of patients with squamous cell carcinoma of the head and neck with no history of tobacco or alcohol use. Acta Otorrinolaringologica Espanola. 2023; 74(1)DOI:10.1016/j.otorri.2022.02.003. PMID:36709798. IF:(Q/D).
01/01/2023 Neutrophil to Lymphocyte Ratio in Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis †
Rodrigo J.P., Sánchez-Canteli M., Triantafyllou A., de Bree R., Mäkitie A.A., Franchi A., Hellquist H., Saba N.F., Stenman G., Takes R.P., Valero C., Zidar N., Ferlito A.. Neutrophil to Lymphocyte Ratio in Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis †. Cancers. 2023; 15(3)DOI:10.3390/cancers15030802. PMID:36765760. IF:4.500(Q1/3D).